ATE207346T1 - Orale pharmazeutische zusammensetzungen mit sexualhormonen - Google Patents

Orale pharmazeutische zusammensetzungen mit sexualhormonen

Info

Publication number: ATE207346T1
Authority: AT; Austria
Prior art keywords: pharmaceutical compositions; compositions containing; oral pharmaceutical; surfactant; propylene glycol
Prior art date: 1996-04-26

Application number

AT97920854T

Other languages

English (en)

Inventor

Elizabeth Anne Perry

Susan Gerrard Chandler

Josephine Joan Chri Ferdinando

Park Monkton

Original Assignee

Scherer Technologies Inc R P

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-04-26

Filing date

1997-04-28

Publication date

2001-11-15

1997-04-28 Application filed by Scherer Technologies Inc R P filed Critical Scherer Technologies Inc R P

2001-11-15 Application granted granted Critical

2001-11-15 Publication of ATE207346T1 publication Critical patent/ATE207346T1/de

Links

229940088597 hormone Drugs 0.000 title 1
239000005556 hormone Substances 0.000 title 1
239000008203 oral pharmaceutical composition Substances 0.000 title 1
230000001568 sexual effect Effects 0.000 title 1
239000004094 surface-active agent Substances 0.000 abstract 4
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 abstract 2
MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 abstract 2
235000014113 dietary fatty acids Nutrition 0.000 abstract 2
229940079593 drug Drugs 0.000 abstract 2
239000003814 drug Substances 0.000 abstract 2
229930195729 fatty acid Natural products 0.000 abstract 2
239000000194 fatty acid Substances 0.000 abstract 2
150000004665 fatty acids Chemical class 0.000 abstract 2
230000002209 hydrophobic effect Effects 0.000 abstract 2
239000003921 oil Substances 0.000 abstract 2
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 abstract 1
BHIZVZJETFVJMJ-UHFFFAOYSA-N 2-hydroxypropyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCC(C)O BHIZVZJETFVJMJ-UHFFFAOYSA-N 0.000 abstract 1
229920003171 Poly (ethylene oxide) Polymers 0.000 abstract 1
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical class CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 abstract 1
239000004359 castor oil Substances 0.000 abstract 1
235000019438 castor oil Nutrition 0.000 abstract 1
229930182833 estradiol Natural products 0.000 abstract 1
125000005456 glyceride group Chemical group 0.000 abstract 1
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 abstract 1
239000003163 gonadal steroid hormone Substances 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
-1 polyoxyethylene Polymers 0.000 abstract 1
239000000186 progesterone Substances 0.000 abstract 1
229960003387 progesterone Drugs 0.000 abstract 1
229940026235 propylene glycol monolaurate Drugs 0.000 abstract 1
229960003604 testosterone Drugs 0.000 abstract 1
150000003626 triacylglycerols Chemical class 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/34—Gestagens

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Dispersion Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AT97920854T 1996-04-26 1997-04-28 Orale pharmazeutische zusammensetzungen mit sexualhormonen ATE207346T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB9608719.2A GB9608719D0 (en)	1996-04-26	1996-04-26	Pharmaceutical compositions
PCT/GB1997/001247 WO1997040823A1 (en)	1996-04-26	1997-04-28	Oral pharmaceutical compositions containing sex hormones

Publications (1)

Publication Number	Publication Date
ATE207346T1 true ATE207346T1 (de)	2001-11-15

Family

ID=10792737

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT97920854T ATE207346T1 (de)	1996-04-26	1997-04-28	Orale pharmazeutische zusammensetzungen mit sexualhormonen

Country Status (12)

Country	Link
EP (1)	EP0904064B1 (de)
JP (1)	JP5088804B2 (de)
KR (1)	KR100511133B1 (de)
AT (1)	ATE207346T1 (de)
AU (1)	AU2707497A (de)
DE (1)	DE69707669T2 (de)
DK (1)	DK0904064T3 (de)
ES (1)	ES2164339T3 (de)
GB (1)	GB9608719D0 (de)
PT (1)	PT904064E (de)
WO (1)	WO1997040823A1 (de)
ZA (1)	ZA973653B (de)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2777784B1 (fr) *	1998-04-27	2004-03-19	Arepa	Composition pharmaceutique a base d'estrogene et de progesterone
US6294192B1 (en)	1999-02-26	2001-09-25	Lipocine, Inc.	Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US7763276B1 (en) *	1999-02-26	2010-07-27	Shionogi & Co., Ltd.	Chewable soft capsules having improved administration properties and process for producing the same
GB9907715D0 (en) *	1999-04-01	1999-05-26	Scherer Corp R P	Pharmaceutical compositions
HU229455B1 (en) *	1999-04-01	2013-12-30	Merck Sharp & Dohme	Formulation comprising testosteron undecanoate and castor oil
US6652880B1 (en)	1999-04-01	2003-11-25	R.P. Scherer Technologies, Inc.	Oral pharmaceutical compositions containing long-chain triglycerides and liphophilic surfactants
US20030236236A1 (en) *	1999-06-30	2003-12-25	Feng-Jing Chen	Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
GB0000313D0 (en)	2000-01-10	2000-03-01	Astrazeneca Uk Ltd	Formulation
KR20030024849A (ko) *	2000-08-10	2003-03-26	델시스 파머수티컬 코포레이션	소수성 약물의 개선된 고형 약제학적 투여 제제
FR2818905A1 (fr) *	2000-12-28	2002-07-05	Cll Pharma	Compositions pharmaceutiques colloidales micellaires renfermant un principe actif lipophile
DE60220519T2 (de)	2001-04-20	2007-09-27	The University Of British Columbia, Vancouver	Mizellares arzneistoffverabreichungssystem für hydrophobe arzneistoffe
EA200301139A1 (ru)	2001-06-21	2004-12-30	Пфайзер Продактс Инк.	Самоэмульгирующиеся препараты ингибиторов белка-переносчика эфиров холестерина
WO2003002095A1 (fr) *	2001-06-28	2003-01-09	Chugai Seiyaku Kabushiki Kaisha	Preparation d'une micro-emulsion de type huile-eau
FR2832065B1 (fr) *	2001-11-13	2004-11-05	Besins Int Belgique	Composition pharmaceutique a base de progesterone micronisee son procede de preparation et ses utilisations
JO2505B1 (en) *	2003-03-14	2009-10-05	باير شيرنغ فارما اكتنجيسيلشافت	Pharmacy methods and formulations for obtaining acceptable serum testosterone levels
CN1299686C (zh) *	2003-04-03	2007-02-14	上海医药工业研究院	黄体酮半固体骨架制剂的组合物
RU2005135565A (ru) *	2003-04-17	2006-07-27	БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE)	Поливитаминная и минеральная добавка для беременных женщин
JP2005047851A (ja) *	2003-07-29	2005-02-24	Nisshin Pharma Inc	ユビデカレノン含有組成物
ATE319426T1 (de)	2003-11-11	2006-03-15	Mattern Udo	Nasenformulierung mit kontrollierter freisetzung von sexualhormonen
US8784869B2 (en)	2003-11-11	2014-07-22	Mattern Pharma Ag	Controlled release delivery system for nasal applications and methods of treatment
CA2604943C (en) *	2005-04-15	2013-09-17	Clarus Therapeutics, Inc.	Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same
US8492369B2 (en)	2010-04-12	2013-07-23	Clarus Therapeutics Inc	Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
CA2664427C (en)	2006-10-04	2012-06-05	M & P Patent Aktiengesellschaft	Controlled release delivery system for nasal application of neurotransmitters
EP1961412A1 (de) *	2006-12-27	2008-08-27	LEK Pharmaceuticals D.D.	Selbstmikroemulgierende Arzneimittelabgabesysteme
GB0807605D0 (en) *	2008-04-28	2008-06-04	Diurnal Ltd	Lipid composition
AU2014200332B2 (en) *	2008-04-28	2016-10-06	Diurnal Limited	Lipid composition
US8309107B2 (en)	2008-10-06	2012-11-13	Banner Pharmacaps, Inc.	Stable solutions of orlistat for pharmaceutical dosage forms
CA2739882A1 (en) *	2008-10-22	2010-04-29	Santen Pharmaceutical Co., Ltd.	Pharmaceutical composition improving intestinal absorption
US11304960B2 (en)	2009-01-08	2022-04-19	Chandrashekar Giliyar	Steroidal compositions
WO2010117873A2 (en)	2009-04-06	2010-10-14	Banner Pharmacaps, Inc.	Progesterone solutions for increased bioavailability
WO2011055269A1 (en) *	2009-11-09	2011-05-12	Pfizer Inc.	Delivery carrier
EP2682111A1 (de)	2009-12-31	2014-01-08	Differential Drug Development Associates LLC	Modulation der Löslichkeit, der Stabilität, der Absorption, des Stoffwechsels und des pharmakokinetischen Profils lipophiler Wirkstoffe mithilfe von Sterolen
NZ602821A (en) *	2010-04-12	2014-07-25	Clarus Therapeutics Inc	Oral testosterone ester formulations and methods of treating testoterone deficiency comprising same
CN103705462B (zh) *	2010-04-12	2016-08-31	克劳拉斯医疗有限公司	口服睾酮酯制剂以及包含其的治疗睾酮缺乏症的方法
US9358241B2 (en)	2010-11-30	2016-06-07	Lipocine Inc.	High-strength testosterone undecanoate compositions
US9034858B2 (en)	2010-11-30	2015-05-19	Lipocine Inc.	High-strength testosterone undecanoate compositions
US20180153904A1 (en)	2010-11-30	2018-06-07	Lipocine Inc.	High-strength testosterone undecanoate compositions
US20120148675A1 (en)	2010-12-10	2012-06-14	Basawaraj Chickmath	Testosterone undecanoate compositions
US8900631B2 (en)	2011-04-28	2014-12-02	Health Science Funding, LLC	Dosage form to increase prasterone bioavailability
US20130045958A1 (en)	2011-05-13	2013-02-21	Trimel Pharmaceuticals Corporation	Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
US9757388B2 (en)	2011-05-13	2017-09-12	Acerus Pharmaceuticals Srl	Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels
AR086400A1 (es)	2011-05-13	2013-12-11	Trimel Pharmaceuticals Corp	Formulaciones en gel intranasal de testosterona en dosis de menor potencia y uso de las mismas para el tratamiento de la anorgasmia o el trastorno de deseo sexual hipoactivo
US8633178B2 (en)	2011-11-23	2014-01-21	Therapeuticsmd, Inc.	Natural combination hormone replacement formulations and therapies
US9301920B2 (en)	2012-06-18	2016-04-05	Therapeuticsmd, Inc.	Natural combination hormone replacement formulations and therapies
FR2988609B1 (fr) *	2012-03-30	2015-09-04	Commissariat Energie Atomique	Formulation pour l'hormonotherapie
US20130338122A1 (en)	2012-06-18	2013-12-19	Therapeuticsmd, Inc.	Transdermal hormone replacement therapies
US10806740B2 (en)	2012-06-18	2020-10-20	Therapeuticsmd, Inc.	Natural combination hormone replacement formulations and therapies
US10806697B2 (en)	2012-12-21	2020-10-20	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
HUE055275T2 (hu) *	2012-06-18	2021-11-29	Therapeuticsmd Inc	Oldható ösztradiol kapszula hüvelyi behelyezésre
FR2997627B1 (fr)	2012-11-08	2015-01-16	Hra Pharma Lab	Produit de co-micronisation comprenant de l'ulipristal acetate
US11246875B2 (en)	2012-12-21	2022-02-15	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en)	2012-12-21	2020-02-25	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en)	2012-12-21	2020-01-21	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en)	2012-12-21	2015-11-10	Therapeuticsmd, Inc.	Soluble estradiol capsule for vaginal insertion
US10471072B2 (en)	2012-12-21	2019-11-12	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en)	2012-12-21	2022-03-08	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
ES2907284T3 (es)	2013-03-15	2022-04-22	Marius Pharmaceuticals Llc	Formulaciones de emulsión
US11744838B2 (en)	2013-03-15	2023-09-05	Acerus Biopharma Inc.	Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event
EP3145489A1 (de)	2014-05-22	2017-03-29	TherapeuticsMD, Inc.	Natürliche kombinierte hormonersatzformulierungen und therapien
WO2015193224A1 (en) *	2014-06-17	2015-12-23	Merck Sharp & Dohme B.V.	Stable formulations of testosterone undecanoate
WO2016033549A2 (en)	2014-08-28	2016-03-03	Lipocine Inc.	(17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
US9498485B2 (en)	2014-08-28	2016-11-22	Lipocine Inc.	Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
US20160361322A1 (en)	2015-06-15	2016-12-15	Lipocine Inc.	Composition and method for oral delivery of androgen prodrugs
US10328087B2 (en)	2015-07-23	2019-06-25	Therapeuticsmd, Inc.	Formulations for solubilizing hormones
WO2017105512A1 (en)	2015-12-18	2017-06-22	Proinvet Innovations S.A.	Formulations and methods for controlling the reproductive cycle and ovulation
WO2017173071A1 (en)	2016-04-01	2017-10-05	Therapeuticsmd, Inc.	Steroid hormone pharmaceutical composition
WO2017173191A1 (en) *	2016-04-01	2017-10-05	Therapeuticsmd, Inc.	Steroid hormone compositions in medium chain oils
WO2017173044A1 (en)	2016-04-01	2017-10-05	Therapeuticsmd Inc.	Steroid hormone compositions in medium chain oils
CA3019375A1 (en) *	2016-04-01	2017-10-05	Therapeuticsmd, Inc.	Steroid hormone pharmaceutical composition
US11559530B2 (en)	2016-11-28	2023-01-24	Lipocine Inc.	Oral testosterone undecanoate therapy
EP3716954A1 (de)	2017-11-27	2020-10-07	Umecrine Cognition AB	Pharmazeutische formulierung von 3-ethynyl-3-hydroxyandrostan-17-on-oxim
WO2020018974A1 (en)	2018-07-20	2020-01-23	Lipocine Inc.	Liver disease
EP3950071A4 (de) *	2019-03-29	2022-12-28	Sekisui Chemical Co., Ltd.	Kern-hülle-struktur, herstellung, arzneimittel zur externen anwendung, bandmittel und kosmetisches produkt
US11564933B2 (en)	2019-04-12	2023-01-31	Tolmar, Inc.	Methods of treating testosterone deficiency
US12403146B2 (en)	2019-10-30	2025-09-02	Marius Pharmaceuticals, Inc.	Preferred oral testosterone undecanoate therapy to achieve testosterone replacement treatment
AU2021216630A1 (en) *	2020-02-05	2022-09-22	Neurocrine UK Limited	Testosterone containing pharmaceutical composition
US11633405B2 (en)	2020-02-07	2023-04-25	Therapeuticsmd, Inc.	Steroid hormone pharmaceutical formulations
GB2626266B (en)	2021-10-08	2026-04-08	Chemo Res S L	Oral pharmaceutical compositions of progesterone and estradiol

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9405304D0 (en) *	1994-03-16	1994-04-27	Scherer Ltd R P	Delivery systems for hydrophobic drugs

1996
- 1996-04-26 GB GBGB9608719.2A patent/GB9608719D0/en active Pending
1997
- 1997-04-25 ZA ZA9703653A patent/ZA973653B/xx unknown
- 1997-04-28 EP EP97920854A patent/EP0904064B1/de not_active Expired - Lifetime
- 1997-04-28 AT AT97920854T patent/ATE207346T1/de active
- 1997-04-28 JP JP53867897A patent/JP5088804B2/ja not_active Expired - Lifetime
- 1997-04-28 ES ES97920854T patent/ES2164339T3/es not_active Expired - Lifetime
- 1997-04-28 PT PT97920854T patent/PT904064E/pt unknown
- 1997-04-28 DK DK97920854T patent/DK0904064T3/da active
- 1997-04-28 AU AU27074/97A patent/AU2707497A/en not_active Abandoned
- 1997-04-28 KR KR1019980708569A patent/KR100511133B1/ko not_active Expired - Lifetime
- 1997-04-28 DE DE69707669T patent/DE69707669T2/de not_active Expired - Lifetime
- 1997-04-28 WO PCT/GB1997/001247 patent/WO1997040823A1/en not_active Ceased

Also Published As

Publication number	Publication date
PT904064E (pt)	2002-02-28
DE69707669D1 (de)	2001-11-29
DE69707669T2 (de)	2002-07-11
JP5088804B2 (ja)	2012-12-05
GB9608719D0 (en)	1996-07-03
DK0904064T3 (da)	2001-12-17
ZA973653B (en)	1997-11-19
KR100511133B1 (ko)	2006-04-28
AU2707497A (en)	1997-11-19
KR20000065025A (ko)	2000-11-06
JP2000510458A (ja)	2000-08-15
WO1997040823A1 (en)	1997-11-06
EP0904064A1 (de)	1999-03-31
ES2164339T3 (es)	2002-02-16
EP0904064B1 (de)	2001-10-24

Legal Events

Date	Code	Title	Description
2002-04-15	UEP	Publication of translation of european patent specification

Publication	Publication Date	Title
ATE207346T1 (de)	2001-11-15	Orale pharmazeutische zusammensetzungen mit sexualhormonen
US5532002A (en)	1996-07-02	Gelatin pharmaceutical formulations
US5738871A (en)	1998-04-14	Pharmaceutical formulations
NO20014719D0 (no)	2001-09-28	Orale farmasöytiske preparater inneholdende lang-kjedete triglyserider og lipofile overflateaktive midler
KR940018091A (ko)	1994-08-16	불포화 지방산을 포함하는 처방
ES2195175T3 (es)	2003-12-01	Preparacion farmaceutica que comprende acido eicosapentaenoico y/o acido estearidonico.
CN101528196A (zh)	2009-09-09	用于生物利用性差的药物的自乳化组合物
PT1152755E (pt)	2002-09-30	Acidos gordos essenciais destinados a prevencao de acidentes cardio-vasculares
ES2101574T3 (es)	1997-07-01	Composicion administrable por via oral apta para formar una microemulsion.
KR970704433A (ko)	1997-09-06	의약 조성물로서의 DHA의 용도(Use of DHA as a pharmaceutical composition)
AR029615A1 (es)	2003-07-10	Una formulacion farmaceutica para la administracion oral
UY26303A1 (es)	2001-03-16	Composiciones farmacéuticas para administración oral y tópica
GR3035613T3 (en)	2001-06-29	Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
ES2180065T3 (es)	2003-02-01	Formulaciones de uso topico que contienen acetato de vitamina e.
IL122434A (en)	2003-07-06	Compositions of mixed colloidal particles in an aqueous environment for sustained delivery of bioactive agents and pharmaceutical preparations therewith
KR930005635A (ko)	1993-04-20	약제학적 조성물
JPH11199493A (ja)	1999-07-27	皮膚外用剤組成物
MY130474A (en)	2007-06-29	Oral pharmaceutical compositions containing long-chain triglycerides and lipophilic surfactants
NZ506579A (en)	2002-11-26	Palatable oral liquid formulations of benzoxazinones hiv reverse transcriptase inhibitors
JP2000159660A (ja)	2000-06-13	シクロスポリンカプセル剤